Cardiovascular Systems Inc. (NASDAQ:CSII) General Counsel Alexander Rosenstein sold 529 shares of the stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $26.80, for a total value of $14,177.20. Following the completion of the sale, the general counsel now owns 34,484 shares of the company’s stock, valued at $924,171.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Cardiovascular Systems Inc. (NASDAQ:CSII) traded down 1.97% during mid-day trading on Monday, reaching $26.39. The company had a trading volume of 250,017 shares. Cardiovascular Systems Inc. has a 12 month low of $7.50 and a 12 month high of $27.38. The firm’s 50 day moving average price is $24.04 and its 200-day moving average price is $20.81. The company’s market capitalization is $872.53 million.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings data on Wednesday, October 26th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.13. The business earned $49.80 million during the quarter, compared to analysts’ expectations of $205.50 million. Cardiovascular Systems had a negative return on equity of 30.19% and a negative net margin of 24.24%. The business’s quarterly revenue was up 13.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.41) EPS. Equities research analysts anticipate that Cardiovascular Systems Inc. will post ($0.21) earnings per share for the current year.

Insider Buying and Selling by Quarter for Cardiovascular Systems (NASDAQ:CSII)

A number of research firms have commented on CSII. Zacks Investment Research upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Monday, August 8th. Needham & Company LLC raised their price objective on Cardiovascular Systems from $23.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, August 4th. Leerink Swann restated an “outperform” rating and issued a $30.00 price objective on shares of Cardiovascular Systems in a research note on Tuesday, November 15th. Feltl & Co. upgraded Cardiovascular Systems from a “buy” rating to a “strong-buy” rating and set a $30.00 price objective for the company in a research note on Thursday, October 27th. Finally, Bank of America Corp. upgraded Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research note on Thursday, August 4th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Cardiovascular Systems presently has an average rating of “Buy” and an average price target of $27.50.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in Cardiovascular Systems by 27.6% in the first quarter. Wellington Management Group LLP now owns 3,018,859 shares of the medical device company’s stock valued at $31,306,000 after buying an additional 652,962 shares in the last quarter. Vanguard Group Inc. boosted its position in Cardiovascular Systems by 13.8% in the second quarter. Vanguard Group Inc. now owns 1,276,110 shares of the medical device company’s stock valued at $23,449,000 after buying an additional 155,207 shares in the last quarter. BlackRock Fund Advisors boosted its position in Cardiovascular Systems by 1.8% in the third quarter. BlackRock Fund Advisors now owns 1,047,959 shares of the medical device company’s stock valued at $24,879,000 after buying an additional 18,685 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its position in Cardiovascular Systems by 19.6% in the third quarter. D. E. Shaw & Co. Inc. now owns 975,483 shares of the medical device company’s stock valued at $23,158,000 after buying an additional 159,558 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Cardiovascular Systems by 1.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 820,526 shares of the medical device company’s stock valued at $19,479,000 after buying an additional 14,748 shares in the last quarter. 69.77% of the stock is owned by institutional investors and hedge funds.

About Cardiovascular Systems

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

5 Day Chart for NASDAQ:CSII

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.